# A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces

> **NCT06151418** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 2313 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Novel hormonal therapy

## Key facts

- **NCT ID:** NCT06151418
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-11-22
- **Primary completion:** 2024-04-23
- **Final completion:** 2024-04-23
- **Target enrollment:** 2313 (ACTUAL)
- **Last updated:** 2025-06-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06151418

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06151418, "A Study to Learn About Novel Hormonal Therapies (NHTs) for Metastatic Castration-sensitive Prostate Cancer (mCSPC) in People Who Were in the Armed Forces". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06151418. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*